Tesaro

News

Gloved hand punches a karate pad held up

GSK unit and AnaptysBio trade lawsuits over Jemperli

A spat between GSK/Tesaro and AnaptysBio over cancer drug Jemperli has escalated into litigation, with both parties claiming breach of contract.

News

GSK enters PARP space with TESARO acquisition

GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its PARP inhibitor Zejula (niraparib).

News

Tesaro stock rockets as rumours of Roche takeover abound

Shares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it.

Views & Analysis

ASCO 2018 - Tuesday 5th June: Tesaro developing checkpoint c...

Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might be about to change following results announced by Tesaro at the American Society of

News

Clovis' PARP drug gets new US ovarian cancer use

Rucaparib gets FDA OK in maintenance use

Oncology

Clovis' Rubraca close to EU approval in ovarian cancer

CHMP backs conditional approval for PARP drug

GSK unit and AnaptysBio trade lawsuits over Jemperli

GSK enters PARP space with TESARO acquisition

Tesaro stock rockets as rumours of Roche takeover abound

ASCO 2018 - Tuesday 5th June: Tesaro developing checkpoint c...

Clovis' PARP drug gets new US ovarian cancer use

Clovis' Rubraca close to EU approval in ovarian cancer

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Tesaro

Editor's Picks